Battered by compounders on Makena, KV seeks bankruptcy protection
This article was originally published in Scrip
Blaming the US FDA for some its woes, KV Pharmaceuticals over the weekend revealed it had filed for Chapter 11 bankruptcy protection, hoping to get out from under its debt.
You may also be interested in...
The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.